Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2025 11:08 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE...
July 16, 2025 09:00 ET | Source: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative...
July 09, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 ...
July 07, 2025 06:00 ET | Source: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative...
July 07, 2025 06:00 ET | Source: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE)...
June 30, 2025 09:06 ET | Source: Greater Cannabis Company, Inc.

GCANRx Announces Uplisting to New Market Tier

BALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
June 30, 2025 08:00 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under...
June 25, 2025 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
June 16, 2025 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
June 11, 2025 15:00 ET | Source: Biofrontera Inc.

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms...

Next Page keyboard_arrow_right